Destiny Pharma PLC (AIM:DEST) chief executive Neil Clark updates Proactive's Thomas Warner on the latest news from the clinical-stage biotech company.
The update follows the announcement that Destiny has reached a collaboration and co-development agreement for its phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence.
Clark says Destiny Pharma is "making real progess" and delivering on its strategy.
Contact Details
Proactive UK Ltd
+44 20 7989 0813
